S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:EQ

Equillium (EQ) Stock Price, News & Analysis

$2.06
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$1.92
$2.13
50-Day Range
$0.74
$3.00
52-Week Range
$0.45
$3.25
Volume
171,229 shs
Average Volume
256,475 shs
Market Capitalization
$72.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.40

Equillium MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.0% Upside
$3.40 Price Target
Short Interest
Bearish
10.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Equillium in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.15) to ($0.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.38 out of 5 stars

Medical Sector

749th out of 939 stocks

Pharmaceutical Preparations Industry

339th out of 422 stocks

EQ stock logo

About Equillium Stock (NASDAQ:EQ)

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.

EQ Stock Price History

EQ Stock News Headlines

Equillium Shares Fall After Swing to 4Q Loss
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Equillium: Q4 Earnings Insights
Equillium (NASDAQ:EQ) Trading Down 3.8%
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
ROOT Sep 2024 7.500 put
SMCI Mar 2024 970.000 call
SMCI Mar 2024 765.000 call
SMCI Mar 2024 800.000 put
SMCI Feb 2024 1460.000 put
SMCI Mar 2024 695.000 put
Equillium Stock (NASDAQ:EQ), Short Interest Report
EQ Bank Card launches in Québec as Carte Banque EQ
See More Headlines
Receive EQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
45
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.40
High Stock Price Target
$4.00
Low Stock Price Target
$2.80
Potential Upside/Downside
+65.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-62,430,000.00
Pretax Margin
-17.96%

Debt

Sales & Book Value

Annual Sales
$36.08 million
Book Value
$0.93 per share

Miscellaneous

Free Float
24,583,000
Market Cap
$72.35 million
Optionable
Not Optionable
Beta
1.64
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Daniel Mark Bradbury (Age 63)
    Executive Chairman
    Comp: $158k
  • Mr. Bruce D. Steel C.F.A. (Age 58)
    Co-Founder, President, CEO & Director
    Comp: $796.95k
  • Ms. Christine Zedelmayer M.B.A. (Age 54)
    P.M.P., Senior VP & COO
    Comp: $561.75k
  • Dr. Stephen Connelly Ph.D. (Age 42)
    Chief Scientific Officer & Director
    Comp: $579.6k
  • Mr. Jason A. KeyesMr. Jason A. Keyes (Age 53)
    Chief Financial Officer
  • Mr. Michael Moore
    Vice President of Investor Relations & Corporate Communications
  • Dr. Matthew Ritter Ph.D.
    Senior Vice President of Corporate Development
  • Mr. Joel M. Rothman (Age 55)
    Chief Development Officer
  • Dr. Maple Fung M.D.
    Chief Medical Officer

EQ Stock Analysis - Frequently Asked Questions

Should I buy or sell Equillium stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EQ shares.
View EQ analyst ratings
or view top-rated stocks.

What is Equillium's stock price target for 2024?

2 equities research analysts have issued 12 month price targets for Equillium's stock. Their EQ share price targets range from $2.80 to $4.00. On average, they anticipate the company's stock price to reach $3.40 in the next year. This suggests a possible upside of 65.0% from the stock's current price.
View analysts price targets for EQ
or view top-rated stocks among Wall Street analysts.

How have EQ shares performed in 2024?

Equillium's stock was trading at $0.7230 at the beginning of the year. Since then, EQ stock has increased by 184.9% and is now trading at $2.06.
View the best growth stocks for 2024 here
.

When is Equillium's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EQ earnings forecast
.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) posted its earnings results on Wednesday, November, 10th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. Equillium had a negative net margin of 36.96% and a negative trailing twelve-month return on equity of 49.78%.

What is Geoffrey A. Rotstein's approval rating as Equillium's CEO?

10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend.

When did Equillium IPO?

Equillium (EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

Who are Equillium's major shareholders?

Equillium's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Decheng Capital LLC (12.66%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Jason A Keyes, Jason A Keyes and Stephen Connelly.
View institutional ownership trends
.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EQ) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners